MCID: ESN005
MIFTS: 55

Eosinophilic Gastroenteritis

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Eosinophilic Gastroenteritis

MalaCards integrated aliases for Eosinophilic Gastroenteritis:

Name: Eosinophilic Gastroenteritis 12 76 59 55 15 73
Eosinophilic Gastroenterocolitis 59
Gastroenteritis, Eosinophilic 76
Eosinophilic Enteropathy 73
Eosinophilic Enteritis 59
Ege 59

Characteristics:

Orphanet epidemiological data:

59
eosinophilic gastroenteritis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



Summaries for Eosinophilic Gastroenteritis

MalaCards based summary : Eosinophilic Gastroenteritis, also known as eosinophilic gastroenterocolitis, is related to esophagitis, eosinophilic, 1 and esophagitis. An important gene associated with Eosinophilic Gastroenteritis is CCL11 (C-C Motif Chemokine Ligand 11), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Fluticasone and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and small intestine, and related phenotypes are eosinophilia and anemia

Wikipedia : 76 Eosinophilic gastroenteritis (EG) is a rare and heterogeneous condition characterized by patchy or... more...

Related Diseases for Eosinophilic Gastroenteritis

Diseases related to Eosinophilic Gastroenteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 esophagitis, eosinophilic, 1 30.8 CCL11 IL5
2 esophagitis 30.8 CCL11 IL5
3 hypereosinophilic syndrome, idiopathic 30.6 IL3 IL5
4 milk allergy 30.2 IL5 RNASE3
5 eosinophilic granuloma 30.0 EPX RNASE3
6 gastroenteritis 30.0 ALB CCL11 IL5 RNASE3
7 churg-strauss syndrome 29.9 IL5 RNASE3
8 allergic bronchopulmonary aspergillosis 29.8 EPX IL5
9 thrombocytosis 29.7 CSF2 IL3
10 dermatitis 29.6 CCL11 IL5 RNASE3
11 allergic asthma 28.4 CCL11 EPX IL5 RNASE3
12 food allergy 28.2 ALB EPX IL5 RNASE3
13 bronchitis 28.0 ALB CCL11 IL5 RNASE3
14 eosinophilic pneumonia 27.8 CCL11 CSF2 IL3 IL5 RNASE3
15 inflammatory bowel disease 27.7 ALB CCL11 EPX IL5
16 hypereosinophilic syndrome 27.3 CCL11 CSF2 EPX IL3 IL5 RNASE3
17 asthma 27.2 CCL11 CSF2 EPX IL3 IL5 RNASE3
18 eosinophilic enteropathy 11.8
19 megalencephaly-capillary malformation-polymicrogyria syndrome 10.9
20 aplastic anemia 10.9
21 exercise-induced anaphylaxis 10.9
22 paroxysmal cold hemoglobinuria 10.9
23 pemphigoid gestationis 10.5 CCL11 IL5
24 chronic meningitis 10.5 CCL11 IL5
25 angiostrongyliasis 10.4 CCL11 IL5
26 strongyloidiasis 10.4 CCL11 IL5
27 eosinophilic meningitis 10.4 CCL11 IL5
28 loeffler endocarditis 10.4 IL5 RNASE3
29 folliculitis 10.4 CCL11 IL5
30 cough variant asthma 10.4 IL5 RNASE3
31 cow milk allergy 10.4 IL5 RNASE3
32 paragonimiasis 10.4 IL5 RNASE3
33 night blindness, congenital stationary, type 1a 10.4 CCL11 IL5
34 latex allergy 10.4 IL5 RNASE3
35 felty syndrome 10.3 CSF2 IL3
36 status asthmaticus 10.3 IL5 RNASE3
37 chronic tic disorder 10.3 CSF2 IL5
38 cellulitis 10.3 IL5 RNASE3
39 sinusitis 10.3 IL5 RNASE3
40 cyclic neutropenia 10.3 CSF2 IL3
41 blepharoconjunctivitis 10.3 CCL11 RNASE3
42 duodenitis 10.3
43 giant papillary conjunctivitis 10.3 CCL11 RNASE3
44 wells syndrome 10.3 IL5 RNASE3
45 anemia of prematurity 10.3 CSF2 IL3
46 pancreatitis 10.2
47 parasitic helminthiasis infectious disease 10.2 IL5 RNASE3
48 endotheliitis 10.2
49 protein-losing enteropathy 10.2
50 mucositis 10.1

Graphical network of the top 20 diseases related to Eosinophilic Gastroenteritis:



Diseases related to Eosinophilic Gastroenteritis

Symptoms & Phenotypes for Eosinophilic Gastroenteritis

Human phenotypes related to Eosinophilic Gastroenteritis:

59 32 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 eosinophilia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001880
2 anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001903
3 vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002013
4 dysphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002015
5 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
6 steatorrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002570
7 hypoalbuminemia 59 32 frequent (33%) Frequent (79-30%) HP:0003073
8 allergic rhinitis 59 32 frequent (33%) Frequent (79-30%) HP:0003193
9 elevated c-reactive protein level 59 32 frequent (33%) Frequent (79-30%) HP:0011227
10 abnormal test result 59 32 frequent (33%) Frequent (79-30%) HP:0500014
11 edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0000969
12 atopic dermatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001047
13 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
14 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
15 asthma 59 32 occasional (7.5%) Occasional (29-5%) HP:0002099
16 protein-losing enteropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002243
17 hematochezia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002573
18 elevated erythrocyte sedimentation rate 59 32 occasional (7.5%) Occasional (29-5%) HP:0003565
19 leukocytosis 59 Frequent (79-30%)
20 diarrhea 59 Frequent (79-30%)
21 malabsorption 59 Frequent (79-30%)
22 abnormality of the gastrointestinal tract 59 Frequent (79-30%)

Drugs & Therapeutics for Eosinophilic Gastroenteritis

Drugs for Eosinophilic Gastroenteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
2
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 63006 5281004
3
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 138530-94-6, 103577-45-3 9578005
4
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
5
Menthol Approved Phase 4 2216-51-5 16666
6 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Cromolyn Sodium Phase 4
19 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
20 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
21 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
22 Proton Pump Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
23 Soy Bean Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable
24 Olive Nutraceutical Phase 4
25
Montelukast Approved Phase 3,Phase 1,Not Applicable 158966-92-8 5281040
26
Esomeprazole Approved, Investigational Phase 2, Phase 3,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
27 Leukotriene Antagonists Phase 3,Phase 1,Not Applicable
28
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
29
Infliximab Approved Phase 2 170277-31-3
30
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
31
Losartan Approved Phase 2 114798-26-4 3961
32
Bethanechol Approved Phase 2 674-38-4 2370
33 Antibodies Phase 2,Phase 1
34 Antibodies, Monoclonal Phase 2,Phase 1
35 Immunoglobulins Phase 2,Phase 1
36 Indoleacetic Acids Phase 2
37 Antirheumatic Agents Phase 2
38 interferons Phase 1, Phase 2
39 Neurotransmitter Agents Phase 2,Not Applicable
40 Pharmaceutical Solutions Phase 2,Not Applicable
41 Angiotensin II Type 1 Receptor Blockers Phase 2
42 Angiotensin Receptor Antagonists Phase 2
43 Angiotensinogen Phase 2
44 Anti-Arrhythmia Agents Phase 2
45 Antihypertensive Agents Phase 2
46 Vasoconstrictor Agents Phase 2
47 mometasone furoate Phase 2
48 Cholinergic Agents Phase 2
49
Lactulose Approved Phase 1 4618-18-2 11333
50
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
3 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Active, not recruiting NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
4 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
5 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
6 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Unknown status NCT02610816 Phase 2, Phase 3 Flovent (fluticasone propionate)
7 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed NCT00635089 Phase 3 reslizumab
8 Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
9 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
10 A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Completed NCT00266578 Phase 3 Fluticasone Propionate
11 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
12 Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
13 Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03245840 Phase 3 Budesonide oral suspension
14 A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Recruiting NCT02605837 Phase 3 OBS;Placebo
15 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Recruiting NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
16 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3 Flovent
17 Safety and Efficacy of Three Doses of Oral Fluticasone Propionate in Adults With Eosinophilic Esophagitis Not yet recruiting NCT02873468 Phase 2, Phase 3 EMS Fluticasone 1;EMS Fluticasone 2;EMS Fluticasone 3
18 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis Completed NCT00762073 Phase 2 budesonide;placebo
19 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
20 Budesonide for Eosinophilic Esophagitis Completed NCT00271349 Phase 2 Budesonide
21 Topical Steroid Treatment for Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
22 Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
23 Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
24 Omalizumab to Treat Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
25 Proof of Concept Study of OC000459 in Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
26 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
27 Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
28 Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
29 Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) Completed NCT02379052 Phase 2 Dupilumab;Placebo
30 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
31 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
32 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
33 Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
34 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis Completed NCT00358449 Phase 2 mepolizumab
35 An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients Completed NCT00274703 Phase 2 mepolizumab
36 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
37 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
38 A Study of AK002 in Patients With Eosinophilic Gastritis With or Without Eosinophilic Gastroenteritis Recruiting NCT03496571 Phase 2 AK002
39 Benralizumab for Eosinophilic Gastritis Recruiting NCT03473977 Phase 1, Phase 2
40 Eosinophilic Esophagitis Clinical Therapy Comparison Trial Recruiting NCT01821898 Phase 2 Oral Budesonide
41 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03191864 Phase 2 APT-1011;Placebo
42 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Recruiting NCT03029091 Phase 2 Losartan Potassium
43 Milk Patch for Eosinophilic Esophagitis Active, not recruiting NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
44 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Active, not recruiting NCT01808196 Phase 2 Losartan Potassium
45 Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study. Enrolling by invitation NCT02113267 Phase 2 Mometasone furoate;Placebo
46 Bethanechol for Eosinophilic Esophagitis Terminated NCT02058537 Phase 2 Bethanechol
47 Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Withdrawn NCT01479231 Phase 1, Phase 2 dexlansoprazole
48 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
49 Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients Completed NCT01641913 Phase 1
50 Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model Completed NCT01040598 Phase 1

Search NIH Clinical Center for Eosinophilic Gastroenteritis

Genetic Tests for Eosinophilic Gastroenteritis

Anatomical Context for Eosinophilic Gastroenteritis

MalaCards organs/tissues related to Eosinophilic Gastroenteritis:

41
Colon, Testes, Small Intestine, T Cells, Liver, Lymph Node, Bone

Publications for Eosinophilic Gastroenteritis

Articles related to Eosinophilic Gastroenteritis:

(show top 50) (show all 405)
# Title Authors Year
1
A Case of Eosinophilic Gastroenteritis in Which Obstructive Jaundice Developed due to Invagination of the Duodenal Wall. ( 29434146 )
2018
2
Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis. ( 29596982 )
2018
3
Eosinophilic gastroenteritis presenting with gastric perforation. ( 29366927 )
2018
4
Successful Food-Elimination Diet in an Adult with Eosinophilic Gastroenteritis. ( 29850645 )
2018
5
Ascites in a Young Woman: A Rare Presentation of Eosinophilic Gastroenteritis. ( 29862093 )
2018
6
Eosinophilic Gastroenteritis and Colitis: Not Yet Ready for the Big Leagues. ( 29620603 )
2018
7
Takayasu's arteritis associated with eosinophilic gastroenteritis, possibly via the overactivation of Th17. ( 29942355 )
2018
8
Eosinophilic gastroenteritis: An unusual presentation of a rare disease. ( 29555104 )
2018
9
Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus. ( 29533199 )
2018
10
Eosinophilic gastroenteritis caused by eating hens' eggs: A case report. ( 28279648 )
2017
11
Eosinophilic gastroenteritis presenting as upper gastrointestinal hematoma and ulcers after endoscopic biopsy: A case report and literature review. ( 28906408 )
2017
12
A Prospective Study on the Prevalence, Extent of Disease and Outcome of Eosinophilic Gastroenteritis in Patients Presenting with Lower Abdominal Symptoms. ( 29212311 )
2017
13
CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis. ( 28497923 )
2017
14
Diagnosis of eosinophilic gastroenteritis is easily missed. ( 28596692 )
2017
15
Eosinophilic Ascites-Rarest Presentation of a Rare Disease, Eosinophilic Gastroenteritis. ( 29313586 )
2017
16
Serum Biomarkers for the Diagnosis of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 28943560 )
2017
17
Eosinophilic Ascites: Uncommon Presentation of Eosinophilic Gastroenteritis in a Young Adult Male. ( 29255753 )
2017
18
Eosinophilic gastroenteritis: three clinical cases with different presentations. ( 28063615 )
2017
19
Post-partum eosinophilic gastroenteritis: A case report. ( 28081983 )
2017
20
Lack of Knowledge and Low Readiness for Health Care Transition in Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 28644350 )
2017
21
Prevalence of Eosinophilic Gastroenteritis and Colitis in a Population-Based Study, From 2012 to 2017. ( 28603057 )
2017
22
Eosinophilic Gastroenteritis Presenting with Red Streaking. ( 28250308 )
2017
23
Hematemesis as Initial Presentation in a 10-Week-Old Infant with Eosinophilic Gastroenteritis. ( 28299223 )
2017
24
Eosinophilic gastroenteritis in a teenager: A rare diagnosis. ( 27283450 )
2017
25
Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate. ( 27466473 )
2016
26
Eosinophilic Esophagitis, Eosinophilic Gastroenteritis, and Eosinophilic Colitis: Common Mechanisms and Differences between East and West. ( 29922659 )
2016
27
Eosinophilic gastroenteritis: a challenge to diagnose and treat. ( 27613263 )
2016
28
A Case of Eosinophilic Gastroenteritis Forming a Rigid Chamber Mimicking Giant Duodenal Ulcer on Computed Tomography Imaging. ( 27086704 )
2016
29
Eosinophilic gastroenteritis in an 18-year-old male with prolonged nephrotic syndrome. ( 28018451 )
2016
30
Severe Eosinophilic Gastroenteritis in a Crohn's Disease Patient Treated With Infliximab and Adalimumab. ( 27018120 )
2016
31
Eosinophilic Gastroenteritis as a Rare Cause of Recurrent Epigastric Pain. ( 27274524 )
2016
32
Eosinophilic gastroenteritis: Approach to diagnosis and management. ( 27867684 )
2016
33
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency. ( 26840762 )
2016
34
Lack of Knowledge and Low Readiness for Healthcare Transition in Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 27657884 )
2016
35
Eosinophilic Gastroenteritis: An Underdiagnosed Condition. ( 27234270 )
2016
36
Eosinophilic gastroenteritis: A state-of-the-art review. ( 27253425 )
2016
37
Severe eosinophilic gastroenteritis. ( 26802190 )
2016
38
Sera of patients with infantile eosinophilic gastroenteritis showed a specific increase in both thymic stromal lymphopoietin and IL-33 levels. ( 26948075 )
2016
39
Eosinophilic Gastroenteritis: Case Report and Review in Search for Diagnostic Key Points. ( 26075112 )
2015
40
Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis. ( 25547198 )
2015
41
A Case of Eosinophilic Gastroenteritis with Ascites. ( 26819619 )
2015
42
Eosinophilic gastroenteritis due to rhus ingestion presenting with gastrointestinal hemorrhage. ( 25844348 )
2015
43
Perforated duodenal ulcer: An unusual manifestation of allergic eosinophilic gastroenteritis. ( 26640348 )
2015
44
Eosinophilic Gastroenteritis with Ascites in a Child. ( 26388635 )
2015
45
Eosinophilic gastroenteritis as an unusual manifestation of multiple mesenteric lymph node enlargements and recurrent diarrheas. ( 26006212 )
2015
46
Obstructive eosinophilic gastroenteritis in a patient with rheumatoid arthritis. ( 26264946 )
2015
47
Systematic Review: The Efficacy of Dietary Treatment for Inducing Disease Remission in Eosinophilic Gastroenteritis. ( 25699593 )
2015
48
Eosinophilic gastroenteritis and bowel obstruction. Can surgery be avoided? ( 25733047 )
2015
49
An Atypical Case of Eosinophilic Gastroenteritis Presenting as Hypovolemic Shock. ( 26078733 )
2015
50
Milk-sensitive eosinophilic gastroenteritis in a 2-month-old boy. ( 26272958 )
2015

Variations for Eosinophilic Gastroenteritis

Expression for Eosinophilic Gastroenteritis

Search GEO for disease gene expression data for Eosinophilic Gastroenteritis.

Pathways for Eosinophilic Gastroenteritis

Pathways related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 CCL11 CSF2 EPX IL3 IL5 RNASE3
2
Show member pathways
12.99 CCL11 CSF2 IL3 IL5
3
Show member pathways
12.95 ALB CSF2 IL3 IL5
4
Show member pathways
12.92 CCL11 CSF2 IL3 IL5
5
Show member pathways
12.25 CSF2 IL3 IL5
6
Show member pathways
12.22 CSF2 IL3 IL5
7
Show member pathways
12.09 CCL11 EPX IL3 IL5 RNASE3
8
Show member pathways
11.97 CCL11 CSF2 IL5
9
Show member pathways
11.79 CSF2 IL3 IL5
10
Show member pathways
11.73 CCL11 IL3 IL5
11 11.64 CSF2 IL3 IL5
12 11.53 CSF2 IL3 IL5
13 11.5 CSF2 IL5
14
Show member pathways
11.38 CSF2 IL3 IL5
15 11.35 CCL11 IL5
16 11.23 CCL11 CSF2 IL5
17 11.16 CCL11 IL5
18 11.01 CSF2 IL3 IL5
19 10.28 CSF2 IL3 IL5

GO Terms for Eosinophilic Gastroenteritis

Cellular components related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ALB CCL11 CSF2 EPX IL3 IL5
2 extracellular space GO:0005615 9.17 ALB CCL11 CSF2 EPX IL3 IL5

Biological processes related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.56 CCL11 CSF2 IL3 IL5
2 MAPK cascade GO:0000165 9.54 CSF2 IL3 IL5
3 peptidyl-tyrosine phosphorylation GO:0018108 9.5 CSF2 IL3 IL5
4 cellular oxidant detoxification GO:0098869 9.46 ALB EPX
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.43 CSF2 IL3
6 positive regulation of DNA replication GO:0045740 9.4 CSF2 IL3
7 regulation of signaling receptor activity GO:0010469 9.26 CCL11 CSF2 IL3 IL5
8 positive regulation of podosome assembly GO:0071803 9.16 CSF2 IL5
9 cytokine-mediated signaling pathway GO:0019221 8.92 CCL11 CSF2 IL3 IL5

Molecular functions related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.43 CSF2 IL3 IL5
2 growth factor activity GO:0008083 9.33 CSF2 IL3 IL5
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.13 CSF2 IL3 IL5
4 cytokine activity GO:0005125 8.92 CCL11 CSF2 IL3 IL5

Sources for Eosinophilic Gastroenteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....